Table 3.
Clinical trials of mRNA vaccine against multi-tumor
| NCT number | Status | Diseases | Phase | Encoding mRNA | Adjuvants | Delivery tools | Additional therapies |
|---|---|---|---|---|---|---|---|
| NCT00529984 | Completed |
Colorectal Cancer; Breast Cancer; Lung Cancer; Pancreatic Cancer; Colon Cancer |
I/II | TAA: CEA | VRP | - | |
| NCT03948763 | Active, not recruiting |
Neoplasms; NSCLC; Pancreatic Neoplasms Colorectal Neoplasms |
I |
TSA: KRAS mutation (G12C, G12D, G12V, G13C) |
- | LNP | pembrolizumab |
| NCT03289962 | Active, not recruiting | Melanoma; NSCLC; Bladder Cancer; Colorectal Cancer; Tripple negative breast cancer; Renal Cancer; Head and Neck Cancer; Other Solid Cancers | I |
TSA: poly-neoepitope |
- | Lipoplex | Atezolizumab |
| NCT03323398 | Terminated | Relapsed/Refractory Solid Tumor Malignancies or Lymphoma; Ovarian Cancer | I | OX40L, IL-23, IL-36γ | - | LNP | Durvalumab |
| NCT03639714 | Active, not recruiting |
NSCLC; Colorectal Cancer; Gastroesophageal Adenocarcinoma; Urothelial Carcinoma |
I/II |
TSA: poly-neoepitope |
Nivolumab; ipilimumab | ||
| NCT00004604 | Completed |
Breast Cancer; Colorectal Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastric Cancer Head and Neck Cancer; Liver Cancer; Lung Cancer; Metastatic Cancer; Ovarian Cancer; Pancreatic Cancer; Testicular Germ Cell Tumor |
I | TAA: CEA | - | DCs-based | - |
| NCT03468244 | Unknown |
Advanced Esophageal Squamous Carcinoma; Gastric Adenocarcinoma; Pancreatic Adenocarcinoma; Colorectal Adenocarcinoma |
- |
TSA: poly-neoepitope |
- | Lipo-polyplex | - |
TAA tumor-associated antigen, TSA tumor specific antigen, LNP Liposome nanoparticles, VRP virus-like replicon particles, CEA carcinoembryonic antigen